BioSpace News Archive

Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced its financial results and business highlights for the first quarter ended March 31, 2020.

Orchard Therapeutics, a global gene therapy leader, announced a new strategic plan to realize the potential of the hematopoietic stem cell gene therapy approach and reported its financial results for the quarter ended March 31, 2020.

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the BofA Securities Virtual Health Care Conference.

Galafold 1Q2020 Revenue of $60.5 Million Reflects Continued Strong Adoption in All Key Global Regions, On Track to Achieve 2020 Revenue Guidance of $250M-$260M

Evogene Ltd., a leading biotechnology company aiming to revolutionize the development of novel products for life-science based industries by utilizing cutting edge computational biology technologies, announces that it will release its financial results for the first quarter 2020 on Tuesday, May 26, 2020.

Company to provide 50 Ion Torrent Genexus Systems for consortia members at a subsidized price to support global COVID-19 research

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the first quarter ended March 31, 2020.

Revenues of $4.4 billion GAAP diluted EPS of $0.06 Non-GAAP diluted EPS of $0.76 Free cash flow of $551 million Full year 2020 business outlook reaffirmed: Net revenues of $16.6 - $17 billion EBITDA of $4.5 - $4.9 billion EPS of $2.30 - $2.55 Free cash flow of $1.8 - $2.2 billion

Rite Aid will significantly expand its COVID-19 testing effort with the addition of 46 no-charge testing sites, most of which will operate through its stores’ drive-through windows, beginning May 11, 2020.

Passage Bio, Inc., a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders and the Gene Therapy Program at the University of Pennsylvania announced the expansion of their collaboration agreement to include an additional five programs and extending Passage Bio’s period to exercise new programs for an additional three years.